2004: Ph.D. in Virology, University Paris 6
1994: Pharm.D., Paris Sud University
1984-1989: Second cycle of pharmaceutical studies, Paris Sud University

2001-present: hospital practitioner in Virology, Hospital Bichat Claude Bernard
1997-2000: Assistant Professor in Virology, Hospital Bichat Claude Bernard, Paris Diderot University
1996-1997: Clinical studies monitoring for ANRS
1990-1994: Resident, Assitance Publique des Hôpitaux de Paris

Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, Descamps D, Chaix ML, Rouzioux C, Plantier JC, ACH2atAAQWG
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.
Journal of Clinical Microbiology 2014, 52, 3017–3022.

Damond F, Benard A, Balotta C, Böni J, Cotten M, Duque V, Ferns B, Garson J, Gomes P, Gonçalves F, Gottlieb G, Kupfer B, Ruelle J, Rodes B, Soriano V, Wainberg M, Taieb A, Matheron S, Chene G, Brun-Vezinet F, ASG
An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.
Journal of Clinical Microbiology 2011, 49, 3491-3497.

Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.
Journal of Clinical Microbiology 2010, 48, 1413-1416.

Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S
Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
AIDS (London, England) 2009, 23, 426-428.

Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S, ACH2CSG
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2009, 23, 1171-1173.

Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S
Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.
AIDS (London, England) 2008, 22, 665-666.

Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, Rodes B, Albert J, Böni J, Garson J, Ferns B, Matheron S, Chene G, Brun-Vezinet F, ACoH2ISG
Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.
Journal of Clinical Microbiology 2008, 46, 2088-2091.

Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, Campa P, Benard A, Chêne G, Brun-Vezinet F
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
Journal of Clinical Microbiology 2005, 43, 4234-4236.

2022

Lebourgeois S, Menidjel R, Chenane HR, Ferré VM, Collin G, Damond F, Coppée R, Yazdanpanah Y, Timsit JF, Houhou-Fidouh N, Descamps D, Charpentier C, Visseaux B
Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
The Journal of Infection 2022, 84, 418-467.

Leducq V, Jary A, Bridier-Nahmias A, Daniel L, Zafilaza K, Damond F, Goldstein V, Duval A, Blanquart F, Calvez V, Descamps D, Marcelin AG, Visseaux B
Nosocomial transmission clusters and lineage diversity characterized by SARS-CoV-2 genomes from two large hospitals in Paris, France, in 2020.
Scientific Reports 2022, 12, 1094.

Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, Bachelard A, Ferré VM, Matheron S, Descamps D, Charpentier C
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
The Journal of Antimicrobial Chemotherapy 2022, 77, 409-412.

Lê MP, Ferré VM, Mazy F, Bourgeois-Moine A, Damond F, Matheron S, Descamps D, Ghosn J, Peytavin G
Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report.
The Journal of Antimicrobial Chemotherapy 2022, 77, 851-853.

Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D, atACH2c
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
AIDS (London, England) 2022

2021

Vauloup-Fellous C, Maylin S, Périllaud-Dubois C, Brichler S, Alloui C, Gordien E, Rameix-Welti MA, Gault E, Moreau F, Fourati S, Challine D, Pawlotsky JM, Houhou-Fidouh N, Damond F, Mackiewicz V, Charpentier C, Méritet JF, Rozenberg F, Podglajen I, Marot S, Petit H, Burrel S, Akhavan S, Leruez-Ville M, Avettand-Fenoel V, Fourgeaud J, Guilleminot T, Gardiennet E, Bonacorsi S, Carol A, Carcelain G, Villemonteix J, Boukli N, Gozlan J, Morand-Joubert L, Legoff J, Delaugerre C, Chaix ML, Roque-Afonso AM, Dortet L, Naas T, Ronat JB, Lepape S, Marcelin AG, Descamps D
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.
European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2021, 40, 2235-2241.

Visseaux B, Collin G, Houhou-Fidouh N, Le Hingrat Q, Ferré VM, Damond F, Ichou H, Descamps D, Charpentier C
Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements.
Journal of Virological Methods 2021, 291, 114086.

Bachelard A, Isernia V, Vallois D, Le Gac S, Chalal L, Landman R, Damond F, Descamps D, Yazdanpanah Y, Peytavin G, Ghosn J
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2484-2485.

Visseaux B, Bertine M, Le Hingrat Q, Ferré V, Charpentier C, Collin F, Damond F, Matheron S, Hué S, Descamps D
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution.
Virus Evolution 2021, 7, veab024.

Ronchetti AM, Matheron S, Galicier L, Damond F, Mahjoub N, Chaghil N, Meignin V, Mechaï F, Simon F, Oksenhendler E, Gérard L
Lymphoma in HIV-2-infected patients in combination antiretroviral therapy era.
AIDS (London, England) 2021, 35, 2299-2309.

Delaroche L, Bertine M, Oger P, Descamps D, Damond F, Genauzeau E, Meicler P, Le Hingrat Q, Lamazou F, Gschwind R, Ruppé E, Visseaux B
Evaluation of SARS-CoV-2 in semen, seminal plasma, and spermatozoa pellet of COVID-19 patients in the acute stage of infection.
PloS One 2021, 16, e0260187.

2020

Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N, FCcmcCCsg, motFCcsg(ao, motCCsgPi, SC, CCCC, Casa, VL, BC, P, S, G
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, S1198-743X(20)30721-7.

Charpentier C, Ichou H, Damond F, Bouvet E, Chaix ML, Ferré V, Delaugerre C, Mahjoub N, Larrouy L, Le Hingrat Q, Visseaux B, Mackiewicz V, Descamps D, Fidouh-Houhou N
Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott).
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2020, 132, 104618.

Cancella de Abreu M, Choquet C, Petit H, Bouzid D, Damond F, Marot S, Ferre VM, Burrel S, Boutolleau D, Houdou-Fidouh N, Marcelin AG, Descamps D, Hausfater P
SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department.
The Journal of Infection 2020, 81, 816-846.

Le Hingrat Q, Visseaux B, Bertine M, Chauveau L, Schwartz O, Collin F, Damond F, Matheron S, Descamps D, Charpentier C
Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity.
Journal of Virology 2020, 94,

2019

Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, FNAfRoAaVH(CH2C
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.

Visseaux B, Le Hingrat Q, Damond F, Charpentier C, Descamps D
[Physiopathology of HIV-2 infection].
Virologie (Montrouge, France) 2019, 23, 277-291.

2018

Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.
Journal of Virological Methods 2018, 257, 12-15.

Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G, A1H2tSG
First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018

Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, AH2CC
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018

Cazals N, Le Hingrat Q, Abraham B, Da Silva P, Guindre L, Goffart S, Damond F, Visseaux B, Charpentier C, Ranger-Rogez S, Descamps D
HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man.
Open Forum Infectious Diseases 2018, 5, ofy223.

2017

Gantner P, Mélard A, Damond F, Delaugerre C, Dina J, Gueudin M, Maillard A, Sauné K, Rodallec A, Tuaillon E, Plantier JC, Rouzioux C, Avettand-Fenoel V, AAQWG
Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies.
Journal of Medical Virology 2017, 89, 2047-2050.

Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix ML, Descamps D, Calvez V, Marcelin AG
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2017, 96, 49-53.

Mamede JI, Damond F, Bernardo Ad, Matheron S, Descamps D, Battini JL, Sitbon M, Courgnaud V
Cyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates.
Scientific Reports 2017, 7, 45214.

Bertine M, Gueudin M, Mélard A, Damond F, Descamps D, Matheron S, Collin F, Rouzioux C, Plantier JC, Avettand-Fenoel V
New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.
Journal of Clinical Microbiology 2017, 55, 2850-2857.

2016

Stora C, Epelboin S, Devouche E, Matheron S, Epelboin L, Yazbeck C, Damond F, Longuet P, Dzineku F, Rajguru M, Delaroche L, Mandelbrot L, Luton D, Patrat C
Women infected with human immunodeficiency virus type 1 have poorer assisted reproduction outcomes: a case-control study.
Fertility and Sterility 2016, 105, 1193-1201.

Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C
Hiv-2 molecular epidemiology.
Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2016, 46, 233-240.

D'Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Piorkowski G, Maquart M, Descamps D, Damond F, Leparc-Goffart I
Evidence of Sexual Transmission of Zika Virus.
The New England Journal of Medicine 2016, 374, 2195-2198.

2015

Gautheret-Dejean A, Bocobza J, Brunet S, Damond F, Plantier JC, Barin F
Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections.
Journal of Medical Virology 2015, 87, 2061–2066.

Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S
Dolutegravir in HIV-2 infected patients with resistant virus to first-line integrase inhibitors from the French Named Patient Program.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.

Visseaux B, Charpentier C, Ozanne A, Nizard A, Drumard S, Fagard C, Glohi D, Damond F, Brun-Vézinet F, Matheron S, Descamps D, ACH2C
Tropism distribution among antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2015, 29, 2209–2212.

Ekouévi DK, Avettand-Fènoël V, Tchounga BK, Coffie PA, Sawadogo A, Minta D, Minga A, Eholie SP, Plantier JC, Damond F, Dabis F, Rouzioux C, IWAc
Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.
PloS One 2015, 10, e0129886.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ACH2C
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.

Leoz M, Feyertag F, Kfutwah A, Mauclère P, Lachenal G, Damond F, De Oliveira F, Lemée V, Simon F, Robertson DL, Plantier JC
The Two-Phase Emergence of Non Pandemic HIV-1 Group O in Cameroon.
PLoS pathogens 2015, 11, e1005029.

Lê MP, Mandelbrot L, Descamps D, Soulié C, Ichou H, Bourgeois-Moine A, Damond F, Lariven S, Valantin MA, Landman R, Faucher P, Tubiana R, Duro D, Meier F, Legac S, Bourse P, Mortier E, Dommergues M, Calvez V, Matheron S, Peytavin G
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Antiviral Therapy 2015, 20, 507-513.

2014

Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK, IWAC
Genotypic resistance profiles of HIV-2-treated patients in West Africa.
AIDS (London, England) 2014, 28, 1161–1169.

Visseaux B, Charpentier C, Rouard C, Fagard C, Glohi D, Tubiana R, Damond F, Brun-Vézinet F, Matheron S, Descamps D, FH2ACC
HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
AIDS (London, England) 2014, 28, 2160–2162.

Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, Descamps D, Chaix ML, Rouzioux C, Plantier JC, ACH2atAAQWG
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.
Journal of Clinical Microbiology 2014, 52, 3017–3022.

Ferraretto X, Estellat C, Damond F, Longuet P, Epelboin S, Demailly P, Yazbeck C, Llabador MA, Pasquet B, Yazdanpanah Y, Matheron S, Patrat C
Timing of intermittent seminal HIV-1 RNA shedding in patients with undetectable plasma viral load under combination antiretroviral therapy.
PloS One 2014, 9, e88922.

2013

Delarue S, Didier E, Damond F, Ponscarme D, Brengle-Pesce K, Resche-Rigon M, Vray M, Gueudin M, Simon F
Highly sensitive plasma RNA quantification by real-time PCR in HIV-2 group A and group B infection.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2013, 58, 461-467.

Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D, ACH2C
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
AIDS (London, England) 2013, 27, 69-80.

Visseaux B, Charpentier C, Taieb A, Damond F, Bénard A, Larrouy L, Chêne G, Brun-Vézinet F, Matheron S, Descamps D, ACH2C
Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
AIDS (London, England) 2013, 27, 292-295.

Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
Transmitted drug resistance in French HIV-2-infected patients.
AIDS 2013, 27, 1671–1674.

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y
Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.
PloS One 2013, 8, e59205.

2012

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F, FAH2CC
Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 55, 1417-1425.

Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, AC0H2C
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.

Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1459-1461.

Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.
The Journal of Antimicrobial Chemotherapy 2012, 67, 2231-2235.

Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Antimicrobial Agents and Chemotherapy 2012, 56, 137-139.

Casalino E, Bernot B, Bouchaud O, Alloui C, Choquet C, Bouvet E, Damond F, Firmin S, Delobelle A, Nkoumazok BE, Der Sahakian G, Viard JP, Zbar OZD, Aslangul E, Krivine A, Zundel J, Ghosn J, Nordmann P, Claessens YE, Tahi T, Riou B, Gautheret-Dejean A, Katlama C, Hausfater P, Brun-Vézinet F, Costagliola D
Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study.
PLoS ONE 2012, 7, e46437.

2011

Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J, Soriano V, Calmy A, Balotta C, Damond F, Brun-Vezinet F, Chene G, Matheron S, ACSG
Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2011, 52, 1257-1266.

Depatureaux A, Charpentier C, Leoz M, Unal G, Damond F, Kfutwah A, Vessière A, Simon F, Plantier JC
Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.
Journal of Acquired Immune Deficiency Syndromes (1999) 2011, 56, 139-145.

Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D, FAH2C(C0V2
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Antimicrobial Agents and Chemotherapy 2011, 55, 1293-1295.

Damond F, Benard A, Balotta C, Böni J, Cotten M, Duque V, Ferns B, Garson J, Gomes P, Gonçalves F, Gottlieb G, Kupfer B, Ruelle J, Rodes B, Soriano V, Wainberg M, Taieb A, Matheron S, Chene G, Brun-Vezinet F, ASG
An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.
Journal of Clinical Microbiology 2011, 49, 3491-3497.

Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Retrovirology 2011, 8, 68.

Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Antiviral Therapy 2011, 16, 937-940.

2010

Frainais C, Vialard F, Rougier N, Aegerther P, Damond F, Ayel JP, Yazbeck C, Hazout A, Selva J
Impact of freezing/thawing technique on sperm DNA integrity in HIV-1 patients.
Journal of Assisted Reproduction and Genetics 2010, 27, 415-421.

Stegmann S, Manea ME, Charpentier C, Damond F, Karmochkine M, Laureillard D, Si-Mohamed A, Weiss L, Piketty C
Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2010, 47, 79-81.

Depatureaux A, Leoz M, De Oliveira F, Gueudin M, Damond F, Descamps D, Brun-Vézinet F, Lemée V, Simon F, Barin F, Plantier JC
[Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data].
Medecine Et Maladies Infectieuses 2010, 40, 669-676.

Burgard M, Jasseron C, Matheron S, Damond F, Hamrene K, Blanche S, Faye A, Rouzioux C, Warszawski J, Mandelbro L, AFPCEC
Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2010, 51, 833-843.

Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
AIDS (London, England) 2010, 24, 2753-2755.

Depatureaux A, Charpentier C, Collin G, Leoz M, Descamps D, Vessière A, Damond F, Rousset D, Brun-Vézinet F, Plantier JC
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.
Antimicrobial Agents and Chemotherapy 2010, 54, 4016-4019.

Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.
Journal of Clinical Microbiology 2010, 48, 1413-1416.

2009

Roquebert B, Damond F, Brun-Vézinet F, Descamps D
[HIV genetic diversity and its consequences].
Pathologie-Biologie 2009, 57, 142-148.

Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F
A new human immunodeficiency virus derived from gorillas.
Nature Medicine 2009, 15, 871-872.

Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S
Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
AIDS (London, England) 2009, 23, 426-428.

Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S, ACH2CSG
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2009, 23, 1171-1173.

Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S, FACCEG
Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl.
AIDS (London, England) 2009, 23, 1997-2004.

Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C
The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection.
Journal of Virology 2009, 83, 4854-4860.

2008

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0V2
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
The Journal of Antimicrobial Chemotherapy 2008, 62, 914-920.

Gueudin M, Damond F, Braun J, Taïeb A, Lemée V, Plantier JC, Chêne G, Matheron S, Brun-Vézinet F, Simon F
Differences in proviral DNA load between HIV-1- and HIV-2-infected patients.
AIDS (London, England) 2008, 22, 211-215.

Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, Dabis F, Brun-Vezinet F, Chêne G, Thiébaut R
Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.
AIDS (London, England) 2008, 22, 457-468.

Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S
Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.
AIDS (London, England) 2008, 22, 665-666.

Leoz M, Depatureaux A, Vessière A, Roquebert B, Damond F, Rousset D, Roques P, Simon F, Plantier JC, ROg
Integrase polymorphism and HIV-1 group O diversity.
AIDS (London, England) 2008, 22, 1239-1243.

Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, AH2CC
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
AIDS (London, England) 2008, 22, 2045-2046.

Costagliola D, Damond F, Palmer P, Rouzioux C, Brun-Vezinet F
One or two enzyme-linked immunosorbent assay tests on the first serum sample for initial diagnosis of HIV-1 infection?.
AIDS (London, England) 2008, 22, 2042-2044.

Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Antimicrobial Agents and Chemotherapy 2008, 52, 1545-1548.

Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, Rodes B, Albert J, Böni J, Garson J, Ferns B, Matheron S, Chene G, Brun-Vezinet F, ACoH2ISG
Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.
Journal of Clinical Microbiology 2008, 46, 2088-2091.

2007

Bouvresse S, Sophie B, Marcelin AG, Anne-Geneviève M, Franck N, Nathalie F, Regnier S, Stéphanie R, Damond F, Florence D, Tulliez M, Micheline T, Dupin N, Nicolas D
The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient.
AIDS (London, England) 2007, 21, 1492-1494.

Barin F, Cazein F, Lot F, Pillonel J, Brunet S, Thierry D, Damond F, Brun-Vézinet F, Desenclos JC, Semaille C
Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006.
AIDS (London, England) 2007, 21, 2351-2353.

Gueudin M, Plantier JC, Lemée V, Schmitt MP, Chartier L, Bourlet T, Ruffault A, Damond F, Vray M, Simon F
Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes.
Journal of Acquired Immune Deficiency Syndromes (1999) 2007, 44, 500-505.

Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, Peeters M, Damond F, Ekouevi DK, Msellati P, Ferradini L, Rukobo S, Maréchal V, Schvachsa N, Wakrim L, Rafalimanana C, Rakotoambinina B, Viard JP, Seigneurin JM, Rouzioux C
Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test.
Journal of Acquired Immune Deficiency Syndromes (1999) 2007, 45, 380-388.

Damond F, Roquebert B, Bénard A, Collin G, Miceli M, Yéni P, Brun-Vezinet F, Descamps D
Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.
Journal of Clinical Microbiology 2007, 45, 3436-3438.

2006

Pasquier C, Anderson D, Andreutti-Zaugg C, Baume-Berkenbosch R, Damond F, Devaux A, Englert Y, Galimand J, Gilling-Smith C, Guist'hau O, Hollander L, Leruez-Ville M, Lesage B, Maillard A, Marcelin Ag, Schmitt MP, Semprini A, Vourliotis M, Xu C, Bujan L, CN
Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation.
Journal of Medical Virology 2006, 78, 877-882.

Fonquernie L, Eholié SP, Damond F, Lacombe K, Girard PM
Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues.
Transactions of the Royal Society of Tropical Medicine and Hygiene 2006, 100, 282-284.

Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, Pueyo S, Brun-Vezinet F, Chene G, ACHCSG
CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort.
AIDS (London, England) 2006, 20, 459-462.

Izzedine H, Damond F, Brocheriou I, Ghosn J, Lassal H, Deray G
HIV-2 infection and HIV-associated nephropathy.
AIDS (London, England) 2006, 20, 949-950.

Descamps D, Damond F, Bénard A, Matheron S, Campa P, Taieb A, Yahyaoui R, Chêne G, Brun-Vézinet F
No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort.
AIDS (London, England) 2006, 20, 1076-1079.

Maniar JK, Damond F, Kamath RR, Mandalia S, Surjushe A
Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma.
International journal of STD & AIDS 2006, 17, 781-782.

Alatrakchi N, Damond F, Matheron S, Beretta-Tempelhoff S, Campa P, Carcelain G, Brun-Vezinet F, Autran B, FH2sg
Proliferative, IFNgamma and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection.
AIDS (London, England) 2006, 20, 29-34.

Descamps D, Ait-Khaled M, Craig C, Delarue S, Damond F, Collin G, Brun-Vézinet F
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Antiviral Therapy 2006, 11, 701-705.

2005

Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.
Journal of Clinical Microbiology 2005, 43, 484-487.

Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, Campa P, Benard A, Chêne G, Brun-Vezinet F
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
Journal of Clinical Microbiology 2005, 43, 4234-4236.

Gueudin M, Damond F, Simon F
Quantification of proviral DNA load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR.
Methods in Molecular Biology (Clifton, N.J.) 2005, 304, 215-220.

Damond F, Collin G, Matheron S, Peytavin G, Campa P, Delarue S, Taieb A, Bénard A, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C5V2
Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
Antiviral Therapy 2005, 10, 861-865.

2002

Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Antimicrobial Agents and Chemotherapy 2002, 46, 570-574.